» Articles » PMID: 39494101

Elucidating the Role of Gut Microbiota Dysbiosis in Hyperuricemia and Gout: Insights and Therapeutic Strategies

Overview
Specialty Gastroenterology
Date 2024 Nov 4
PMID 39494101
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperuricemia (HUA) is a condition associated with a high concentration of uric acid (UA) in the bloodstream and can cause gout and chronic kidney disease. The gut microbiota of patients with gout and HUA is significantly altered compared to that of healthy people. This article focused on the complex interconnection between alterations in the gut microbiota and the development of this disorder. Some studies have suggested that changes in the composition, diversity, and activity of microbes play a key role in establishing and progressing HUA and gout pathogenesis. Therefore, we discussed how the gut microbiota contributes to HUA through purine metabolism, UA excretion, and intestinal inflammatory responses. We examined specific changes in the composition of the gut microbiota associated with gout and HUA, highlighting key bacterial taxa and the metabolic pathways involved. Additionally, we discussed the effect of conventional gout treatments on the gut microbiota composition, along with emerging therapeutic approaches that target the gut microbiome, such as the use of probiotics and prebiotics. We also provided insights into a study regarding the gut microbiota as a possible novel therapeutic intervention for gout treatment and dysbiosis-related diagnosis.

Citing Articles

Microbial Guardians or Foes? Metagenomics Reveal Association of Gut Microbiota in Intestinal Toxicity Caused by DON in Mice.

Cui Y, Guan H, Okyere S, Hua Z, Deng Y, Deng H Int J Mol Sci. 2025; 26(4).

PMID: 40004174 PMC: 11855166. DOI: 10.3390/ijms26041712.


Role of species in pathogenesis, immune regulation, and prognostic tools for managing ulcerative colitis and Crohn's disease.

Patnaik S, Durairajan S, Singh A, Krishnamoorthi S, Iyaswamy A, Mandavi S World J Gastroenterol. 2024; 30(48):5212-5220.

PMID: 39735273 PMC: 11612695. DOI: 10.3748/wjg.v30.i48.5212.

References
1.
Mackenzie I, Ford I, Nuki G, Hallas J, Hawkey C, Webster J . Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264):1745-1757. DOI: 10.1016/S0140-6736(20)32234-0. View

2.
Dalbeth N, L Gosling A, Gaffo A, Abhishek A . Gout. Lancet. 2021; 397(10287):1843-1855. DOI: 10.1016/S0140-6736(21)00569-9. View

3.
Wang H, Mei L, Deng Y, Liu Y, Wei X, Liu M . Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis. Nutrition. 2019; 62:63-73. DOI: 10.1016/j.nut.2018.11.018. View

4.
Lin S, Zhang T, Zhu L, Pang K, Lu S, Liao X . Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota. J Genet Genomics. 2021; 48(9):781-791. DOI: 10.1016/j.jgg.2021.06.009. View

5.
Xie W, Yang X, Deng Z, Zheng Y, Zhang R, Wu L . Effects of Washed Microbiota Transplantation on Serum Uric Acid Levels, Symptoms, and Intestinal Barrier Function in Patients with Acute and Recurrent Gout: A Pilot Study. Dig Dis. 2021; 40(5):684-690. DOI: 10.1159/000521273. View